Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Decision brief
Answer first · skim in under a minute
Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The move could improve convenience, reduce infusion-related burden, and shape investor expectations for Eisai and Biogen stock.
Eisai and Biogen stock focus shifted on Aug. 29, 2025, when the FDA approved Leqembi IQLIK for weekly subcutaneous maintenance in early Alzheimer's. After 18 months of IV dosing, patients can move to a 360 mg weekly autoinjector or keep less frequent IV infusions.
Contents10 sections
Key Takeaways
- FDA approved Leqembi IQLIK (lecanemab-irmb) subcutaneous maintenance on Aug. 29, 2025.
- Autoinjector dose is 360 mg/1.8 mL (200 mg/mL), given once weekly in about 15 seconds.
- Maintenance starts after 18 months of IV Leqembi at 10 mg/kg every 2 weeks.
- IV maintenance alternative remains 10 mg/kg every 4 weeks; U.S. launch was set for Oct. 6, 2025.
What did FDA approve for Leqembi IQLIK?
Eisai and Biogen said the FDA cleared a BLA for once-weekly lecanemab-irmb subcutaneous injection branded Leqembi IQLIK. The product is for maintenance in mild cognitive impairment or mild dementia due to Alzheimer's disease.
The companies positioned the autoinjector as an option after the standard IV start. See the PR Newswire FDA approval release.
How does the label define starting vs maintenance?
The FDA label says start with IV Leqembi at 10 mg/kg every 2 weeks. Confirm amyloid pathology first. Obtain a baseline brain MRI and follow ARIA imaging rules.
After 18 months, clinicians may continue every-2-week IV dosing or move to maintenance. Maintenance choices are IV 10 mg/kg every 4 weeks or subcutaneous 360 mg once weekly with Leqembi IQLIK. Full text is in the FDA prescribing information PDF.
- Starting IV: 10 mg/kg every 2 weeks
- IV maintenance: 10 mg/kg every 4 weeks
- SC maintenance: 360 mg weekly via IQLIK
When did U.S. availability begin?
Company materials said Leqembi IQLIK would launch in the U.S. on Oct. 6, 2025. A later PR Newswire note announced U.S. availability of the subcutaneous maintenance dose.
Biogen’s investor release matches the Aug. 29, 2025 approval date and the early-AD maintenance framing. Read the Biogen investor release.
What DailyMed says about switching routes
DailyMed restates the starting and maintenance tables. If moving from starting IV to maintenance, give the first maintenance dose two weeks after the last starting dose.
Patients may switch between IV and subcutaneous maintenance. Start the new route one week after the last maintenance dose of the prior route. Missed subcutaneous doses may be given up to 6 days late, then resume the usual day. See DailyMed Leqembi / IQLIK.
ARIA risk still governs access
Leqembi carries a boxed warning for amyloid-related imaging abnormalities. ApoE ε4 homozygotes face higher ARIA risk. Testing for ApoE ε4 status should occur before start, with counseling on genotype risk.
Subcutaneous maintenance does not remove MRI monitoring duties tied to the class. Clinics still need imaging capacity and clear stop/restart rules when ARIA appears.
What remains unproven for commercial upside
Approval and launch do not prove how many patients will switch from infusion chairs to weekly home injection. Payer prior auth, caregiver training, and ARIA logistics can still limit conversion.
For Eisai and Biogen stock, the near-term question is persistence and share versus other anti-amyloid options, not just the new device approval itself.
Related NovaPharma coverage
- Lecanemab (Leqembi) drug profile
- Biogen company profile
- Eisai company profile
- GSK Blenrep returns to the US market
Frequently Asked Questions
What did the FDA approve for Leqembi?
On Aug. 29, 2025, the FDA approved Leqembi IQLIK, a once-weekly 360 mg subcutaneous autoinjector for maintenance dosing in early Alzheimer's disease after 18 months of IV Leqembi.
How does subcutaneous maintenance dosing work?
After 18 months of IV Leqembi at 10 mg/kg every 2 weeks, patients may continue IV at 10 mg/kg every 4 weeks or switch to weekly 360 mg subcutaneous Leqembi IQLIK.
Why does this matter for Eisai and Biogen stock?
Easier at-home maintenance may support persistence and capacity. Actual revenue impact still depends on uptake, payer rules, and ARIA monitoring adherence.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Leqembi.
Unlock full calendar →Biogen pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
